These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8491237)

  • 1. Dose-dependent uricosuric effect of ambroxol.
    Oosterhuis B; Storm G; Cornelissen PJ; Su CA; Sollie FA; Jonkman JH
    Eur J Clin Pharmacol; 1993; 44(3):237-41. PubMed ID: 8491237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uricosuric effect of irtemazole in healthy subjects.
    Gresser U; Zöllner N
    Klin Wochenschr; 1989 Oct; 67(19):971-5. PubMed ID: 2615290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.
    Shen Z; Gillen M; Miner JN; Bucci G; Wilson DM; Hall JW
    Drug Des Devel Ther; 2017; 11():2077-2086. PubMed ID: 28744099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uricosuric effect of CGS-12970, a new thromboxane synthase inhibitor.
    Saris SD; Piraino AJ; Morgan JM; Hirschhorn WL; Meidl E; Schaffer AV
    Clin Pharmacol Ther; 1993 Jul; 54(1):65-9. PubMed ID: 8330466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uric acid plasma level and urine pH in rats treated with ambroxol.
    Drewa T; Wolski Z; Gruszka M; Misterek B; Lysik J
    Acta Pol Pharm; 2007; 64(6):565-7. PubMed ID: 18323253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of urate-lowering therapies on renal handling of uric acid.
    Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
    Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
    Khosravan R; Grabowski BA; Wu JT; Joseph-Ridge N; Vernillet L
    Clin Pharmacokinet; 2006; 45(8):821-41. PubMed ID: 16884320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uricosuric effect of different doses of irtemazole in normouricaemic subjects.
    Gresser U; Kamilli I; Kronawitter U; Zöllner N
    Eur J Clin Pharmacol; 1990; 38(5):489-91. PubMed ID: 2379534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diuretic and uricosuric effects of traxanox sodium in healthy subjects. Single dose study.
    Ebihara A; Tsuru M; Ohashi K; Fujimura A; Kondo K
    Arzneimittelforschung; 1987 Dec; 37(12):1388-91. PubMed ID: 3329516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of different doses of Irtemazole in repeated application.
    Kamilli I; Gresser U; Zöllner N
    Z Rheumatol; 1991; 50(1):23-8. PubMed ID: 1905451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative measurements of the urinary excretion of creatinine, uric acid, hypoxanthine and xanthine, uracil, cyclic AMP, and cyclic GMP in healthy newborn infants.
    Manzke H; Spreter von Kreudenstein P; Dörner K; Kruse K
    Eur J Pediatr; 1980 Mar; 133(2):157-61. PubMed ID: 6244960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldose reductase inhibitory and uricosuric activities of FK366 in healthy volunteers.
    Kanamaru M; Uematsu T; Nagashima S; Mizuno A; Terakawa M; Sugiyama A; Nakashima M
    J Clin Pharmacol; 1993 Nov; 33(11):1122-31. PubMed ID: 8300896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males.
    Shen Z; Rowlings C; Kerr B; Hingorani V; Manhard K; Quart B; Yeh LT; Storgard C
    Drug Des Devel Ther; 2015; 9():3423-34. PubMed ID: 26170627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of uricosuric drugs and diuretics on uric acid excretion in oxonate-treated rats.
    Yonetani Y; Iwaki K
    Jpn J Pharmacol; 1983 Oct; 33(5):947-54. PubMed ID: 6645117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uricosuric effects of niridazole.
    Weintraub M; Nash TE; Ottesen E; Becker MA
    Clin Pharmacol Ther; 1977 Nov; 22(5 Pt 1):568-72. PubMed ID: 913024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal excretion of hypoxanthine and xanthine in primary gout.
    Puig JG; Mateos FA; Jiménez ML; Ramos TH
    Am J Med; 1988 Oct; 85(4):533-7. PubMed ID: 3177401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects.
    Yoon S; Shin D; Lee H; Jang IJ; Yu KS
    Drug Des Devel Ther; 2015; 9():5033-49. PubMed ID: 26357467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Uric Acid-Lowering Agents on Endothelial Function: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Borgi L; McMullan C; Wohlhueter A; Curhan GC; Fisher ND; Forman JP
    Hypertension; 2017 Feb; 69(2):243-248. PubMed ID: 28028194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The uricosuric action of azapropazone: dose-response and comparison with probenecid.
    Higgens CS; Scott JT
    Br J Clin Pharmacol; 1984 Sep; 18(3):439-43. PubMed ID: 6487482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.